KD Logo

Zentalis Pharmaceuticals Inc [ZNTL] Insider Gallagher Cam sells 9,597 Shares – Company Insider Activity

Zentalis Pharmaceuticals Inc’s recent filing unveils that its President, Interim CFO Gallagher Cam unloaded Company’s shares for reported $0.11 million on May 31 ’24. In the deal valued at $11.98 per share,9,597 shares were sold. As a result of this transaction, Gallagher Cam now holds 633,680 shares worth roughly $2.26 million.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free
Sponsored

Then, HAUSMAN DIANA sold 3,356 shares, generating $42,353 in total proceeds. Upon selling the shares at $12.62, the Chief Medical Officer now owns 373,876 shares.

Before that, Epperly Melissa B, sold 2,573 shares. Zentalis Pharmaceuticals Inc shares valued at $29,435 were divested by the Chief Financial Officer at a price of $11.44 per share. As a result of the transaction, Epperly Melissa B, now holds 451,449 shares, worth roughly $1.61 million.

UBS downgraded its Zentalis Pharmaceuticals Inc [ZNTL] rating to a Neutral from a a Buy in a research note published on June 20, 2024; the price target was decreased to $5 from $28. A number of analysts have revised their coverage, including Wells Fargo’s analysts, who decreased its forecast for the stock in mid June from “an Overweight” to “an Equal weight”. Wedbush also remained covering ZNTL and has decreased its forecast on June 18, 2024 with a “an Underperform” recommendation from previously “Neutral” rating. Morgan Stanley revised its rating on June 18, 2024. It rated ZNTL as “an Equal-weight” which previously was an “an Overweight”.

Price Performance Review of ZNTL

On Tuesday, Zentalis Pharmaceuticals Inc [NASDAQ:ZNTL] saw its stock fall -14.80% to $3.57. Over the last five days, the stock has lost -15.00%. Zentalis Pharmaceuticals Inc shares have fallen nearly -76.44% since the year began. Nevertheless, the stocks have fallen -87.34% over the past one year. While a 52-week high of $29.04 was reached on 02/28/24, a 52-week low of $3.93 was recorded on 07/02/24. SMA at 50 days reached $9.97, while 200 days put it at $13.52. A total of 1.3 million shares were traded, compared to the trading of 1.19 million shares in the previous session.

Levels Of Support And Resistance For ZNTL Stock

The 24-hour chart illustrates a support level at 3.26, which if violated will result in even more drops to 2.96. On the upside, there is a resistance level at 4.05. A further resistance level may holdings at 4.53. The Relative Strength Index (RSI) on the 14-day chart is 18.78, which indicates oversold technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -1.74, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bearish at 98.14%. Stochastics%K at 2.69% indicates the stock is a buying.

Most Popular